KALV 241018 10.00C (KALV241018C10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

KALV241018C10000

Watchlist

2.00
+1.60+400.00%

15min DelayClose Sep 27 16:00 ET

2.00High2.00Low

Intraday

5D
Daily

News

KalVista Pharmaceuticals Up Over 19%, on Pace for Largest Percent Increase Since February 2021 -- Data Talk
Dow Jones13:25 ET
KalVista Pharmaceuticals Initiated at Buy by Jones Trading
Dow JonesSep 27 09:48 ET · Ratings
JonesTrading Initiates KalVista Pharmaceuticals(KALV.US) With Buy Rating, Announces Target Price $35
Moomoo NewsSep 27 07:31 ET · Ratings
Buy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Phase 3 Data and Market Potential
TipRanksSep 27 07:25 ET · Ratings
Express News | Kalvista Pharmaceuticals Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $35
ReutersSep 27 07:14 ET
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
BusinesswireSep 10 07:00 ET

Comments

Moomoo AI

Feb 22 12:58

The recent share sale by the CEO and the absence of insider buying over the past year may raise concerns. The low level of insider ownership compared to most companies is also somewhat worrying. Caution is advised when considering buying KalVista Pharmaceuticals stock.

Have KalVista Pharmaceuticals Insiders Been Selling Stock?

Meltyy

Jan 31 14:38

Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$Regenxbio (RGNX.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Vertex Pharmaceuticals (VRTX.US)$ Phase 3
$KalVista Pharmaceuticals (KALV.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$Applied Therapeutics (APLT.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3...

JESSE JAMES8832

Jan 28 08:33

could be something brewing here

$KalVista Pharmaceuticals (KALV.US)$

Moomoo AI

Oct 22, 2023 09:04

The termination of the KVD824 trial may impact KalVista's financials and stock price, but the company remains focused on advancing its other drug, sebetralstat, and its oral Factor XIIa inhibitor program for HAE prophylaxis.

KalVista Stock Slumps 37% as KVD824 Trial for Hereditary Angioedema Ended Over Liver Safety Concerns